دورية أكاديمية
Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients.
| العنوان: | Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients. |
|---|---|
| المؤلفون: | Costedoat, Ingrid, Wallaert, Martin, Gaultier, Aurelie, Vasseur, Robin, Vanhaecke, Clelia, Viguier, Manuelle, Cordelette, Charles, Denoyer, Alexandre, Ferrier le Bouëdec, Marie‐Christine, Coutu, Adrien, Lamiaux, Marie, Tran, Thi Ha Châu, Lacour, Jean Philippe, Elmaleh, Valerie, Tetart, Florence, Gueudry, Julie, Tauber, Marie, Giordano‐Labadie, Francoise, Cassagne, Myriam, Nosbaum, Audrey |
| المصدر: | Journal of the European Academy of Dermatology & Venereology; May2023, Vol. 37 Issue 5, p1056-1063, 8p |
| مصطلحات موضوعية: | ATOPIC dermatitis, DRY eye syndromes, LONGITUDINAL method, SCIENTIFIC observation, DUPILUMAB, HEAD & neck cancer |
| مستخلص: | Background: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective: To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events. Methods: A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab. Results: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis. Limitations: Our follow‐up period was 16 weeks and some late‐onset time effects may still occur. Conclusion: This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of the European Academy of Dermatology & Venereology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
| ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 163092674 1007 6 Academic Journal academicJournal 1006.75848388672 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=163092674&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Costedoat%2C+Ingrid%22">Costedoat, Ingrid</searchLink><br /><searchLink fieldCode="AR" term="%22Wallaert%2C+Martin%22">Wallaert, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Gaultier%2C+Aurelie%22">Gaultier, Aurelie</searchLink><br /><searchLink fieldCode="AR" term="%22Vasseur%2C+Robin%22">Vasseur, Robin</searchLink><br /><searchLink fieldCode="AR" term="%22Vanhaecke%2C+Clelia%22">Vanhaecke, Clelia</searchLink><br /><searchLink fieldCode="AR" term="%22Viguier%2C+Manuelle%22">Viguier, Manuelle</searchLink><br /><searchLink fieldCode="AR" term="%22Cordelette%2C+Charles%22">Cordelette, Charles</searchLink><br /><searchLink fieldCode="AR" term="%22Denoyer%2C+Alexandre%22">Denoyer, Alexandre</searchLink><br /><searchLink fieldCode="AR" term="%22Ferrier le Bouëdec%2C+Marie‐Christine%22">Ferrier le Bouëdec, Marie‐Christine</searchLink><br /><searchLink fieldCode="AR" term="%22Coutu%2C+Adrien%22">Coutu, Adrien</searchLink><br /><searchLink fieldCode="AR" term="%22Lamiaux%2C+Marie%22">Lamiaux, Marie</searchLink><br /><searchLink fieldCode="AR" term="%22Tran%2C+Thi+Ha+Châu%22">Tran, Thi Ha Châu</searchLink><br /><searchLink fieldCode="AR" term="%22Lacour%2C+Jean+Philippe%22">Lacour, Jean Philippe</searchLink><br /><searchLink fieldCode="AR" term="%22Elmaleh%2C+Valerie%22">Elmaleh, Valerie</searchLink><br /><searchLink fieldCode="AR" term="%22Tetart%2C+Florence%22">Tetart, Florence</searchLink><br /><searchLink fieldCode="AR" term="%22Gueudry%2C+Julie%22">Gueudry, Julie</searchLink><br /><searchLink fieldCode="AR" term="%22Tauber%2C+Marie%22">Tauber, Marie</searchLink><br /><searchLink fieldCode="AR" term="%22Giordano‐Labadie%2C+Francoise%22">Giordano‐Labadie, Francoise</searchLink><br /><searchLink fieldCode="AR" term="%22Cassagne%2C+Myriam%22">Cassagne, Myriam</searchLink><br /><searchLink fieldCode="AR" term="%22Nosbaum%2C+Audrey%22">Nosbaum, Audrey</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Journal of the European Academy of Dermatology & Venereology; May2023, Vol. 37 Issue 5, p1056-1063, 8p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22ATOPIC+dermatitis%22">ATOPIC dermatitis</searchLink><br /><searchLink fieldCode="DE" term="%22DRY+eye+syndromes%22">DRY eye syndromes</searchLink><br /><searchLink fieldCode="DE" term="%22LONGITUDINAL+method%22">LONGITUDINAL method</searchLink><br /><searchLink fieldCode="DE" term="%22SCIENTIFIC+observation%22">SCIENTIFIC observation</searchLink><br /><searchLink fieldCode="DE" term="%22DUPILUMAB%22">DUPILUMAB</searchLink><br /><searchLink fieldCode="DE" term="%22HEAD+%26+neck+cancer%22">HEAD & neck cancer</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Background: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective: To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events. Methods: A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab. Results: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis. Limitations: Our follow‐up period was 16 weeks and some late‐onset time effects may still occur. Conclusion: This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Journal of the European Academy of Dermatology & Venereology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/jdv.18932
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 1056
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => ATOPIC dermatitis
[Type] => general
)
[1] => Array
(
[SubjectFull] => DRY eye syndromes
[Type] => general
)
[2] => Array
(
[SubjectFull] => LONGITUDINAL method
[Type] => general
)
[3] => Array
(
[SubjectFull] => SCIENTIFIC observation
[Type] => general
)
[4] => Array
(
[SubjectFull] => DUPILUMAB
[Type] => general
)
[5] => Array
(
[SubjectFull] => HEAD & neck cancer
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Costedoat, Ingrid
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wallaert, Martin
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gaultier, Aurelie
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vasseur, Robin
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vanhaecke, Clelia
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Viguier, Manuelle
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cordelette, Charles
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Denoyer, Alexandre
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ferrier le Bouëdec, Marie‐Christine
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Coutu, Adrien
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lamiaux, Marie
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tran, Thi Ha Châu
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lacour, Jean Philippe
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Elmaleh, Valerie
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tetart, Florence
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gueudry, Julie
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tauber, Marie
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giordano‐Labadie, Francoise
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cassagne, Myriam
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nosbaum, Audrey
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 05
[Text] => May2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 09269959
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 37
)
[1] => Array
(
[Type] => issue
[Value] => 5
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal of the European Academy of Dermatology & Venereology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |